Page last updated: 2024-10-25

clobazam and Drug Refractory Epilepsy

clobazam has been researched along with Drug Refractory Epilepsy in 22 studies

Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.
clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.

Research Excerpts

ExcerptRelevanceReference
"A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)."7.83Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016)
"Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam."7.81Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015)
" Other factors, including dosage and clobazam co-therapy, were significantly associated with a greater effect on seizure control and side effects of CBD."7.01Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023)
"The average number of seizures per month during the previous 3 months before CNB treatment was 19."5.91Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023)
"ANT stimulation and seizure freedom were associated with distinct, dissimilar spectral changes in RNS-derived electrophysiology."5.91Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023)
"Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures."5.48Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018)
"Clobazam (CLB) is a well characterized antiepileptic drug (AED) that differs from other benzodiazepines by its basic chemical structure and pharmacodynamic properties."5.43Effects of clobazam for treatment of refractory status epilepticus. ( Gerner, ST; Geyer, A; Gollwitzer, S; Hamer, HM; Huttner, HB; Knappe, RU; Kuramatsu, JB; Madžar, D, 2016)
" The mean baseline seizure frequency before initiation of clobazam was 2 (range 1-30) seizures per month."4.31Tolerability of clobazam as add-on therapy in patients aged 50 years and older with drug-resistant epilepsy. ( Bunch, ME; Frawley, B; Lynch, TM; Nagarajan, E, 2023)
"We identified a significant decrease in the serum concentrations of clobazam, desmethylclobazam, and lamotrigine following a 12-week ketogenic diet intervention in children with drug resistant epilepsy."4.31Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet. ( Gervin, K; Iversen, PO; Kverneland, M; Landmark, CJ; Pedersen, S; Rudi, K; Selmer, KK, 2023)
"Cannabidiol (CBD) has been shown to reduce seizures among patients with refractory epilepsies of various etiologies in recent clinical trials and an expanded access program (EAP)."4.02The long-term efficacy of cannabidiol in the treatment of refractory epilepsy. ( Bruno, PL; Fleming, B; Grinspoon, R; Patel, S; Skirvin, LA; Thiele, EA; Wade, C; Wolper, E, 2021)
"A 12-year-old boy with intractable epilepsy had tonic and atonic seizures despite treatment with valproic acid (3000mg/day), levetiracetam (3000mg/day) and clobazam (40mg/day)."3.83Aggravation of atonic seizures by rufinamide: A case report. ( Aydın, A; Aydınlı, N; Bektaş, G; Çalışkan, M; Özmen, M; Pembegül Yıldız, E; Tatlı, B, 2016)
"Clobazam treatment tailored to the timing of patient's seizures may improve seizure control."3.83Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy. ( Fernández, IS; Jackson, M; Kadish, NE; Klehm, J; Loddenkemper, T; Manganaro, S; Thome-Souza, S, 2016)
"Stiripentol is an antiepileptic drug (AED) approved by the European Medicines Agency for the treatment of Dravet Syndrome (DS) as adjunct treatment with valproate and clobazam."3.81Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy. ( Specchio, N; Trivisano, M; Vigevano, F, 2015)
"Epidiolex® (CBD) is FDA-approved for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC)."3.30Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy. ( Felton, E; Georgieva, D; Gidal, BE; Hartkopf, K; Hawk, L; Hsu, D; Langley, J; Margolis, A; Struck, A, 2023)
" Other factors, including dosage and clobazam co-therapy, were significantly associated with a greater effect on seizure control and side effects of CBD."3.01Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. ( Aparasu, R; Estes, E; Reddy, DS; Talwar, A, 2023)
" In the secondary analyses, participants were divided into groups depending on whether they were taking at least 1/4 of the other AEDs shown to interact with CBD (iAED)."2.90Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. ( Ampah, SB; Bebin, EM; Cutter, GR; Gaston, TE; Grayson, LP; Liu, Y; Szaflarski, JP, 2019)
" Cannabidiol is rapidly absorbed and its  bioavailability increases when administered with high fat meals."2.66Clinical pharmacology of cannabidiol in refractory epilepsy. ( Cáceres-Guido, P; Maldonado, C; Riva, N; Schaiquevich, P; Vázquez, M, 2020)
"The average number of seizures per month during the previous 3 months before CNB treatment was 19."1.91Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies. ( Aguilar-Castillo, MJ; Cabezudo-García, P; Carreño, M; Ciano-Petersen, NL; Estivill-Torrús, G; García-Martín, G; Gutierrez-Cardo, AL; López-Moreno, Y; Oliver, B; Ortega-Pinazo, J; Ramírez-García, T; Rodríguez-Uranga, JJ; Romero-Godoy, J; Sanchez-Godoy, L; Serrano-Castro, PJ, 2023)
"ANT stimulation and seizure freedom were associated with distinct, dissimilar spectral changes in RNS-derived electrophysiology."1.91Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography. ( Brandman, DM; Bullinger, K; Gross, RE; Isbaine, F; Skelton, HM, 2023)
"Mean reduction in weekly seizure frequency was greater at the best point of seizure control within the first year than at two months of treatment with CBD, regardless of concomitant CLB usage (all p > 0."1.56Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam. ( Anagnos, CJ; Bruno, PL; Savage, TE; Skirvin, LA; Sourbron, J; Thiele, EA; Wolper, ES, 2020)
"Conclusions Depressive disorders are common, underdiagnosed and undertreated in patients with refractory MTLE."1.48Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy. ( Cendes, F; de Oliveira Cardoso, TAM; Gonçalves, EB; Yasuda, CL, 2018)
"Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures."1.48Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center. ( Carson, RP; Carter, EG; Doll, ED; Fu, C; Porcari, GS, 2018)
"Nocturnal frontal lobe epilepsy (NFLE) is an idiopathic partial epilepsy with a family history in about 25% of cases, with autosomal dominant inheritance (autosomal dominant NFLE [ADNFLE])."1.46Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy. ( Aroni, S; Marrosu, F; Melis, M; Milioli, G; Muntoni, AL; Parrino, L; Pillolla, G; Pistis, M; Puligheddu, M; Sagheddu, C; Terzano, GM, 2017)
"Clobazam (CLB) is an antiepileptic drug that is metabolized to the major metabolite N-desmethylclobazam (N-CLB)."1.46Correlating blood and urinary concentrations of clobazam doses in Japanese children and adolescents with intractable epilepsy. ( Ishida, T; Ishii, M; Iwasaki, T; Nonoda, Y; Toki, T, 2017)
"Clobazam (CLB) is a well characterized antiepileptic drug (AED) that differs from other benzodiazepines by its basic chemical structure and pharmacodynamic properties."1.43Effects of clobazam for treatment of refractory status epilepticus. ( Gerner, ST; Geyer, A; Gollwitzer, S; Hamer, HM; Huttner, HB; Knappe, RU; Kuramatsu, JB; Madžar, D, 2016)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's10 (45.45)24.3611
2020's12 (54.55)2.80

Authors

AuthorsStudies
Talwar, A1
Estes, E1
Aparasu, R1
Reddy, DS1
Georgieva, D1
Langley, J1
Hartkopf, K1
Hawk, L1
Margolis, A1
Struck, A1
Felton, E1
Hsu, D1
Gidal, BE1
Nagarajan, E1
Lynch, TM1
Frawley, B1
Bunch, ME1
Pedersen, S1
Kverneland, M1
Rudi, K1
Gervin, K1
Landmark, CJ1
Iversen, PO1
Selmer, KK1
Serrano-Castro, PJ1
Rodríguez-Uranga, JJ1
Cabezudo-García, P1
García-Martín, G1
Romero-Godoy, J1
Estivill-Torrús, G1
Ciano-Petersen, NL1
Oliver, B1
Ortega-Pinazo, J1
López-Moreno, Y1
Aguilar-Castillo, MJ1
Gutierrez-Cardo, AL1
Ramírez-García, T1
Sanchez-Godoy, L1
Carreño, M1
Skelton, HM1
Brandman, DM1
Bullinger, K1
Isbaine, F1
Gross, RE1
Savage, TE1
Sourbron, J1
Bruno, PL2
Skirvin, LA2
Wolper, ES1
Anagnos, CJ1
Thiele, EA2
Mandelbaum, DE1
Lattanzi, S1
Brigo, F1
Trinka, E1
Schaiquevich, P1
Riva, N1
Maldonado, C1
Vázquez, M1
Cáceres-Guido, P1
Villanueva, V1
Carreño-Martínez, M1
Gil Nagel-Rein, A1
López-González, FJ1
Patel, S1
Grinspoon, R1
Fleming, B1
Wade, C1
Wolper, E1
Puligheddu, M1
Melis, M1
Pillolla, G1
Milioli, G1
Parrino, L1
Terzano, GM1
Aroni, S1
Sagheddu, C1
Marrosu, F1
Pistis, M1
Muntoni, AL1
Gonçalves, EB1
de Oliveira Cardoso, TAM1
Yasuda, CL1
Cendes, F1
Porcari, GS1
Fu, C1
Doll, ED1
Carter, EG1
Carson, RP1
Incecik, F1
Ozcanyüz, DG1
Gaston, TE1
Bebin, EM1
Cutter, GR1
Ampah, SB1
Liu, Y1
Grayson, LP1
Szaflarski, JP1
Trivisano, M1
Specchio, N1
Vigevano, F1
Bektaş, G1
Çalışkan, M1
Aydın, A1
Pembegül Yıldız, E1
Tatlı, B1
Aydınlı, N1
Özmen, M1
Thome-Souza, S1
Klehm, J1
Jackson, M1
Kadish, NE1
Manganaro, S1
Fernández, IS1
Loddenkemper, T1
Iwasaki, T1
Nonoda, Y1
Ishida, T1
Toki, T1
Ishii, M1
Madžar, D1
Geyer, A1
Knappe, RU1
Gollwitzer, S1
Kuramatsu, JB1
Gerner, ST1
Hamer, HM1
Huttner, HB1

Reviews

3 reviews available for clobazam and Drug Refractory Epilepsy

ArticleYear
Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis.
    Experimental neurology, 2023, Volume: 359

    Topics: Adult; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug Resistant Epilepsy; Epilepsies, Myoclonic

2023
Clinical pharmacology of cannabidiol in refractory epilepsy.
    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2020, 06-30, Volume: 44, Issue:5

    Topics: Anticonvulsants; Cannabidiol; Clobazam; Drug Resistant Epilepsy; Humans; Quality of Life

2020
New therapeutic approach in Dravet syndrome and Lennox-Gastaut syndrome with cannabidiol.
    Revista de neurologia, 2021, Apr-30, Volume: 72, Issue:S01

    Topics: Administration, Oral; Adolescent; Algorithms; Anticonvulsants; Cannabidiol; Child; Child, Preschool;

2021

Trials

2 trials available for clobazam and Drug Refractory Epilepsy

ArticleYear
Real-world, long-term evaluation of the tolerability and therapy retention of Epidiolex® (cannabidiol) in patients with refractory epilepsy.
    Epilepsy & behavior : E&B, 2023, Volume: 141

    Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Drug Resistant E

2023
Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
    Epilepsy & behavior : E&B, 2019, Volume: 98, Issue:Pt A

    Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Clobazam; Drug Interactions; Drug Resistant

2019

Other Studies

17 other studies available for clobazam and Drug Refractory Epilepsy

ArticleYear
Tolerability of clobazam as add-on therapy in patients aged 50 years and older with drug-resistant epilepsy.
    Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2023, Volume: 44, Issue:8

    Topics: Aged; Anticonvulsants; Benzodiazepines; Clobazam; Drug Resistant Epilepsy; Drug Therapy, Combination

2023
Decreased serum concentrations of antiseizure medications in children with drug resistant epilepsy following treatment with ketogenic diet.
    Epilepsia open, 2023, Volume: 8, Issue:3

    Topics: Anticonvulsants; Child; Clobazam; Diet, Ketogenic; Drug Resistant Epilepsy; Epilepsy; Humans; Infant

2023
Cenobamate and Clobazam Combination as Personalized Medicine in Autoimmune-Associated Epilepsy With Anti-Gad65 Antibodies.
    Neurology(R) neuroimmunology & neuroinflammation, 2023, Volume: 10, Issue:6

    Topics: Clobazam; Drug Resistant Epilepsy; Epilepsy; gamma-Aminobutyric Acid; Humans; Precision Medicine; Pr

2023
Distinct Biomarkers of ANT Stimulation and Seizure Freedom in an Epilepsy Patient with Ambulatory Hippocampal Electrocorticography.
    Stereotactic and functional neurosurgery, 2023, Volume: 101, Issue:6

    Topics: Biomarkers; Clobazam; Deep Brain Stimulation; Drug Resistant Epilepsy; Electrocorticography; Epileps

2023
Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
    Epilepsy research, 2020, Volume: 160

    Topics: Adolescent; Adult; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Drug Resistant E

2020
Re: Efficacy of Cannabidiol in Subjects with Refractory Epilepsy Relative to Concomitant Use of Clobazam.
    Epilepsy research, 2022, Volume: 180

    Topics: Anticonvulsants; Benzodiazepines; Cannabidiol; Clobazam; Drug Resistant Epilepsy; Humans; Seizures

2022
Cannabidiol efficacy and clobazam coadministration: Where do we stand now?
    Epilepsia, 2020, Volume: 61, Issue:8

    Topics: Anticonvulsants; Cannabidiol; Clobazam; Drug Resistant Epilepsy; Humans

2020
The long-term efficacy of cannabidiol in the treatment of refractory epilepsy.
    Epilepsia, 2021, Volume: 62, Issue:7

    Topics: Adolescent; Anticonvulsants; Cannabidiol; Child; Child, Preschool; Clobazam; Dose-Response Relations

2021
Rationale for an adjunctive therapy with fenofibrate in pharmacoresistant nocturnal frontal lobe epilepsy.
    Epilepsia, 2017, Volume: 58, Issue:10

    Topics: Adult; Animals; Anticonvulsants; Benzodiazepines; Carbamazepine; Clobazam; Disease Models, Animal; D

2017
Depressive disorders in patients with pharmaco-resistant mesial temporal lobe epilepsy.
    The Journal of international medical research, 2018, Volume: 46, Issue:2

    Topics: Adult; Anticonvulsants; Antidepressive Agents; Benzodiazepines; Carbamazepine; Clobazam; Depressive

2018
Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
    Epilepsy & behavior : E&B, 2018, Volume: 80

    Topics: Adolescent; Anticonvulsants; Attention; Cannabidiol; Cannabis; Child; Child, Preschool; Clobazam; Dr

2018
Unusual side effects due to clobazam: a case report with edema of the extremities.
    Acta neurologica Belgica, 2018, Volume: 118, Issue:3

    Topics: Anticonvulsants; Child; Clobazam; Drug Resistant Epilepsy; Edema; Extremities; Humans; Male

2018
Extending the use of stiripentol to other epileptic syndromes: a case of PCDH19-related epilepsy.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2015, Volume: 19, Issue:2

    Topics: Age of Onset; Anticonvulsants; Autistic Disorder; Benzodiazepines; Cadherins; Child; Clobazam; Cogni

2015
Aggravation of atonic seizures by rufinamide: A case report.
    Brain & development, 2016, Volume: 38, Issue:7

    Topics: Anticonvulsants; Benzodiazepines; Brain; Child; Clobazam; Drug Resistant Epilepsy; Drug Therapy, Com

2016
Clobazam higher-evening differential dosing as an add-on therapy in refractory epilepsy.
    Seizure, 2016, Volume: 40

    Topics: Anticonvulsants; Benzodiazepines; Case-Control Studies; Child; Child, Preschool; Clobazam; Drug Chro

2016
Correlating blood and urinary concentrations of clobazam doses in Japanese children and adolescents with intractable epilepsy.
    Biomedical chromatography : BMC, 2017, Volume: 31, Issue:4

    Topics: Administration, Oral; Adolescent; Anticonvulsants; Asian People; Benzodiazepines; Child; Child, Pres

2017
Effects of clobazam for treatment of refractory status epilepticus.
    BMC neurology, 2016, Oct-21, Volume: 16, Issue:1

    Topics: Aged; Anticonvulsants; Benzodiazepines; Clobazam; Drug Resistant Epilepsy; Female; Humans; Male; Mid

2016